Search Results - Dintsios, C.M.

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    When suddenly the evaluation became a validation

    When suddenly the evaluation became a validation by Dintsios, C.M, Niederstadt, C

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform

    Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health C... by Dintsios, C.M, Knoerzer, D, Duenne, A.A, Schwartz, F.W, Ruof, J

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments

    PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments by Ruof, J, Dintsios, C.M, Schwartz, F

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    PHP178 Validity of Self-Reported Health Care Utilization: Towards a Research Consensus

    PHP178 Validity of Self-Reported Health Care Utilization: Towards a Research Consensus by Chernyak, N, Jülich, F, Droste, S, Icks, A, Dintsios, C.M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    PSS24 How Do Glaucoma Patients Assess Different Aspects of Their Treatment: An Elicitation of Patients' Preferences Using the Analytic Hierarchy Process

    PSS24 How Do Glaucoma Patients Assess Different Aspects of Their Treatment: An Elicitation of Patients' Preferences Using the Analytic Hierarchy Process by Dintsios, C.M, Scheibler, F.F, Janssen, I, Gerber, A, Chernyak, N, Finger, R

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective

    PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective by Dabisch, I, Dethling, J, Dintsios, C.M, Drechsler, M, Kalanovic, D, Kaskel, P, Langer, F, Ruof, J, Ruppert, T, Wirth, D

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

    PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMIT... by Dintsios, C.M., Worm, F., Ruof, J., Herpers, M.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

    The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany by Dintsios, C. M, Beinhauer, I

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    PRM5 - Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform

    PRM5 - Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog H... by Dintsios, C.M., Knoerzer, D., Duenne, A.A., Schwartz, F.W., Ruof, J.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY

    PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY by Mühlbacher, A., Bridges, J.F., Bethge, S., Dintsios, C.M., Schwalm, A., Nübling, M.

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  11. 11
    Wo steht die Kosten-Nutzen-Bewertung des IQWiG: Abgleich mit einem internationalen Referenzszenario?

    Wo steht die Kosten-Nutzen-Bewertung des IQWiG: Abgleich mit einem internationalen Referenzszenario? by Schwalm, A., Danner, M., Seidl, A., Volz, F., Dintsios, C.M., Gerber, A.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  12. 12
    PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY

    PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY by Mühlbacher, A, Bridges, J.F, Bethge, S, Dintsios, C.M, Schwalm, A, Nübling, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: